Deutetrabenazine is Used for managing movement disorders associated with neurological conditions. It was first introduced by Teva Branded Pharmaceutical Products R And D Llc in its drug Austedo on Apr 3, 2017. Another drug containing Deutetrabenazine is Austedo Xr. 3 different companies have introduced drugs containing Deutetrabenazine.

Deutetrabenazine Patents

Given below is the list of patents protecting Deutetrabenazine, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Austedo Xr	US11311488	Osmotic dosage forms comprising deutetrabenazine and methods of use thereof	Jun 10, 2041	Teva
Austedo	US11179386 (Pediatric)	Analogs of deutetrabenazine, their preparation and use	Sep 15, 2038	Teva Branded Pharm
Austedo	US11813232 (Pediatric)	Analogs of deutetrabenazine, their preparation and use	Sep 15, 2038	Teva Branded Pharm
Austedo Xr	US11179386 (Pediatric)	Analogs of deutetrabenazine, their preparation and use	Sep 15, 2038	Teva
Austedo Xr	US11813232 (Pediatric)	Analogs of deutetrabenazine, their preparation and use	Sep 15, 2038	Teva
Austedo	US11179386	Analogs of deutetrabenazine, their preparation and use	Mar 15, 2038	Teva Branded Pharm
Austedo	US11813232	Analogs of deutetrabenazine, their preparation and use	Mar 15, 2038	Teva Branded Pharm
Austedo Xr	US11179386	Analogs of deutetrabenazine, their preparation and use	Mar 15, 2038	Teva
Austedo Xr	US11813232	Analogs of deutetrabenazine, their preparation and use	Mar 15, 2038	Teva
Austedo	US10959996 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo	US11357772 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo	US11446291 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo	US11564917 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo	US11648244 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo	US12016858 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva Branded Pharm
Austedo Xr	US10959996 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo Xr	US11357772 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo Xr	US11446291 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo Xr	US11564917 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo Xr	US11648244 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo Xr	US12016858 (Pediatric)	Methods for the treatment of abnormal involuntary movement disorders	Sep 07, 2036	Teva
Austedo	US10959996	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo	US11357772	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo	US11446291	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo	US11564917	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo	US11648244	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo	US12016858	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva Branded Pharm
Austedo Xr	US10959996	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo Xr	US11357772	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo Xr	US11446291	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo Xr	US11564917	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo Xr	US11648244	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo Xr	US12016858	Methods for the treatment of abnormal involuntary movement disorders	Mar 07, 2036	Teva
Austedo	US11666566 (Pediatric)	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva Branded Pharm
Austedo	US9233959 (Pediatric)	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva Branded Pharm
Austedo	US9296739 (Pediatric)	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva Branded Pharm
Austedo	US9550780 (Pediatric)	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva Branded Pharm
Austedo	US9814708 (Pediatric)	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva Branded Pharm
Austedo Xr	US9550780 (Pediatric)	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar 18, 2034	Teva
Austedo	US11666566	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva Branded Pharm
Austedo	US9233959	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva Branded Pharm
Austedo	US9296739	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva Branded Pharm
Austedo	US9550780	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva Branded Pharm
Austedo	US9814708	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva Branded Pharm
Austedo Xr	US9550780	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Sep 18, 2033	Teva
Austedo	US8524733 (Pediatric)	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Oct 03, 2031	Teva Branded Pharm
Austedo Xr	US8524733 (Pediatric)	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Oct 03, 2031	Teva
Austedo	US8524733	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr 03, 2031	Teva Branded Pharm
Austedo Xr	US8524733	Benzoquinoline inhibitors of vesicular monoamine transporter 2	Apr 03, 2031	Teva

Add above patents to watchlist

Deutetrabenazine's Family Patents

Full family tree

Deutetrabenazine Generic API Manufacturers

Several generic applications have been filed for Deutetrabenazine.

Given below is the list of companies who have filed for Deutetrabenazine generic, along with the locations of their manufacturing plants worldwide.